VENTYX BIOSCIENCES, INC.

VTYX21 Jan 2025
Healthcare
$2.03
-0.03 (-3.22%)
Lowest Today
$1.93
Highest Today
$2.1
Today’s Open
$2.03
Prev. Close
$2.02
52 Week High
$11.48
52 Week Low
$1.67
To Invest in VENTYX BIOSCIENCES, INC.

VENTYX BIOSCIENCES, INC.

Healthcare
VTYX21 Jan 2025
-0.03 (-3.22%)
1M
3M
6M
1Y
5Y
Low
$1.92
Day’s Range
High
$2.1
1.92
52 Week Low
$1.67
52-Week Range
52 Week High
$11.48
1.67
1 Day
-
1 Week
+3.58%
1 month return
-12.17%
3 month return
-15.48%
6 month return
-20.47%
1 Year return
+2.53%
3 Years return
-86.5%
5 Years return
-
10 Years return
-
Institutional Holdings
Deerfield Management Co
9.5
BlackRock Inc
6.95
Citadel Advisors Llc
6.3
Vanguard Group Inc
4.9
Farallon Capital Management, L.L.C.
4.48
TANG CAPITAL MANAGEMENT LLC
4.38
Octagon Capital Advisors LP
3.38

Market Status

Fundamentals
Market Cap
142.84 mln
PB Ratio
0.51
PE Ratio
0
Enterprise Value
-120.95 mln
Total Assets
277.69 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
Organisation
VENTYX BIOSCIENCES, INC.
Employees
75
Industry
Biotechnology
CEO
Dr. Raju S. Mohan Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step